Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

(20%) of patients experienced at least 1 episode of >/= Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Additional information about Millennium is available through its website, http://www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important r
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015  The annual customer satisfaction survey of ... EMR as #1 across all specialties. Every year, ... conducts a poll of EHR users and publishes an ... Praxis EMR topped 348 other systems, ... based criteria used by Black Book. In addition to ...
(Date:5/29/2015)... DIEGO and BOSTON , ... leader in instrument development, custom automation, and contract manufacturing, ... of the Nanopatch™ needle-free drug delivery technology, have been ... development of the Nanopatch Jet Coating Instrument , ... delivery research and product development.  The award was announced ...
(Date:5/29/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at the JMP Securities Life Sciences Conference in ... rd , 2015 at 11:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jmp27/hae ... a global healthcare company dedicated to providing innovative blood ...
Breaking Medicine Technology:Praxis EMR Ranks #1 for Physician Satisfaction in Black Book's 2015 Survey of Solo and Small Practices 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3
... June 23, 2011 ULURU Inc. (NYSE AMEX: ... Gilford Securities Incorporated ("Gilford") to serve as the Company,s financial ... banking services and is a full service national investment firm ... engagement includes assisting the Company to broaden its investor base ...
...   MacroGenics, Inc., a privately held biotechnology company that ... diseases, today announced that 1-year data from Protege, the ... 1 diabetes patients, will be presented at the American ... California on June 28, 2011 at 9:10 a.m. PDT. ...
Cached Medicine Technology:ULURU Inc. Announces the Engagement of Gilford Securities Incorporated to Serve as the Company's Financial Advisor 2MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28 2
(Date:5/30/2015)... VA (PRWEB) May 30, 2015 ... Foundation interviewed Dr. Charles Simone and Dr. Evan ... during its ‘Meet the Mesothelioma Experts’ series. The ... focusing on mesothelioma centers of excellence. Drs. Simone ... executive director, Mary Hesdorffer, with whom they discussed ...
(Date:5/30/2015)... Nicole Blodgett, Vice President of Secura ... designation to further her expertise in the income ... insurance advisors, health care professionals, and financial planners ... associated with the risk and the cost with ... the latest accomplishment in Nicole's journey with Secura ...
(Date:5/30/2015)... San Luis Obispo, CA (PRWEB) May 30, 2015 ... Susan Polk announced today that she is offering a ... insurance. , The offer coincides with Disability Awareness ... Life Happens . Industry members across the United States ... as a time to raise awareness about the possibility ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 A live ... of medical equipment from hospitals, surgery centers and other ... equipment will be sold including radiology, surgery, endoscopy, lab, ... auction will take place Tuesday, June 2nd starting at ... warehouse located at 5025 North Hiatus Rd., Sunrise, FL ...
(Date:5/29/2015)... 29, 2015 Based in St. Louis, Missouri ... shirts for a couple of months now and are ... release, which reads “I’m not misbehaving, I have Autism, please ... parent’s of an autistic child in order to start a ... Not only are they raising awareness through the autism awareness ...
Breaking Medicine News(10 mins):Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2Health News:Centurion to Sell Surplus Medical Equipment in Online and On-site Auction 2Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2
... to ... the Rules for Healthcare Payors, BURLINGTON, Mass., April ... benefit administration, business,intelligence and portal software products for healthcare ... investment commitment from,Psilos Group, a leading healthcare venture capital ...
... XR, Will Earn a 16 Percent Patient Share in the Bipolar ... ... Decision Resources, WALTHAM, Mass., April 22 Decision Resources, one of ... that a therapy that carries a lower risk of weight,gain than AstraZeneca,s ...
... Diversified Agency Services, a,division of Omnicom Group Inc. ... healthcare and pharmaceutical agencies Cline Davis Mann, Corbett and,Flashpoint ... at the 19th Annual,Manny Awards., Cline Davis Mann ... all,agencies with annual revenue of more than $50 million. ...
... MONICA, Calif., April 22 Aida,Pharmaceuticals, Inc. ... of an investor-focused corporate synopsis on its ... be downloaded as a,pdf document. The synopsis ... current product line, the drugs in its,development ...
... 22 WallSt.net,s 3-Minute,Press Show is a daily ... Shows air Monday through Friday on:, http://tv.wallst.net/3-min-press/3-min-press.php ... interviews with,public company executives on their company and ... provide viewers with insight into a company,s most,recent ...
... American College of Allergy,Asthma & Immunology (ACAAI) recently ... highlight the importance of improving care for those,who ... important,information for physicians and patients are available today ... who are,committed to driving the dialogue about unmet ...
Cached Medicine News:Health News:HealthEdge Receives $13 Million Investment Commitment to Fund Significant Growth 2Health News:A Drug That Carries a Lower Risk of Weight Gain Than AstraZeneca's Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment 2Health News:Omnicom's Diversified Agency Services Healthcare Agencies Top Med Ad News' Manny Awards 2Health News:Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website 2Health News:Featured Stocks on Today's Edition of WallSt.net's 3-Minute Press Show: CYRX, RHWI 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This dissector offers dual-action jaws, which are long, tapered, and angled 30 to simplify even difficult laparoscopic dissection....
Medicine Products: